engleski

Stem cell transplantation for multiple myeloma in Croatia: Evaluation of the efficacy of double stem cell transplantation

Clinical trials so far have shown that high-dose therapy and autologous hematopoietic stem cell transplantation (ASCT) improves response rates, disease-free survival (DSF), and overall survival (OS) in symptomatic patients with multiple myeloma (MM) younger than 65 years. In addition, transplant related mortality is relatively low. However, the vast majority of patients eventually develop progressive disease with the median time to relapse of approximately 3 years. Recent nonrandomized and randomized studies indicate survival benefit for multiple myeloma patients treated with double ASCT as compared to single transplant. We conducted a prospective trial of two successive high-dose chemo- or chemoradiotherapy followed by peripheral blood stem cell rescue for patients with advanced stage multiple myeloma. The aim of the study was to evaluate feasibility, efficacy, and toxicity of this treatment approach.

Multiple myeloma ; stem cell transplantation

nije evidentirano